Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Defeat On Amgen’s Otezla Pushes US Generic Opportunity Back To 2028

Zydus Cadila Also On Receiving End Of Unfavorable Ruling

Executive Summary

Amgen is set to enjoy its monopoly on the Otezla oral treatment for plaque psoriasis until late into the decade, after ANDA sponsors Sandoz and Zydus Cadila failed to find a way around the originator’s intellectual property, including a key patent expiring early in 2028.

You may also be interested in...



Induced Infringement And Price Fixing Among Legal Headlines In 2021

In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.

Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End

Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.

Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued

In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel